Annual report pursuant to Section 13 and 15(d)

Summary of significant accounting policies (Tables)

v3.7.0.1
Summary of significant accounting policies (Tables)
12 Months Ended
Jul. 31, 2017
Accounting Policies [Abstract]  
Schedule Of Segment Revenue And Revenue Percentage [Table Text Block] The following table summarizes the Clinical Lab segment’s net revenues and revenue percentages by revenue category:

    Years Ended July 31,
    2017     2016     2015  
Revenue category   Amount     %     Amount     %     Amount     %  
Third-party payers   $ 43,059       56     $ 34,454       49     $ 30,685       49  
Patient self-pay     11,380       15       14,744       21       11,028       17  
Medicare     12,705       16       11,392       16       11,981       19  
HMO’s     10,263       13       10,325       14       9,720       15  
Total   $ 77,407       100 %   $ 70,915       100 %   $ 63,414       100 %
Schedule Of Accounts Receivable By Segment [Table Text Block] The following is a table of the Company’s net accounts receivable by segment.

    July 31, 2017     July 31, 2016  
Net accounts receivable by segment   Amount     %     Amount     %  
Clinical Labs (by billing category)                                
Third party payers   $ 7,256       64     $ 5,861       57  
Patient self-pay     1,591       14       1,676       16  
Medicare     1,385       12       1,486       14  
HMO’s     1,169       10       1,341       13  
Total Clinical Labs     11,401       100 %     10,364       100 %
                                 
Total Life Sciences     3,779               4,228          
Total accounts receivable – net   $ 15,180             $ 14,592          
Schedule of Allowance for Doubtful Accounts Receivable [Table Text Block] Changes in the Company’s allowance for doubtful accounts are as follows:

     July 31, 2017     July 31, 2016  
Beginning balance   $ 3,517     $ 1,786  
Provision for doubtful accounts     2,775       2,336  
Write-offs     (2,716 )     (605 )
Ending balance   $ 3,576     $ 3,517  
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] The following table sets forth the computation of basic and diluted net loss per share for the years ended July 31:

    2017     2016     2015  
Net (loss) income   $ (2,504 )   $ 45,286     $ (2,285 )
                         
Weighted-average common shares outstanding - basic     46,350       46,153       45,355  
Add: effect of dilutive stock options and restricted stock           449        
Weighted-average common shares outstanding - diluted     46,350       46,602       45,355  
                         
Net (loss) income per share – basic   $ (0.05 )   $ 0.98     $ (0.05 )
Net (loss) income per share – diluted   $ (0.05 )   $ 0.97     $ (0.05 )
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] The following table sets forth the amount of expense related to share-based payment arrangements included in specific line items in the accompanying statement of operations for the years ended July 31:

    2017     2016     2015  
Cost of clinical laboratory services   $ 6     $ 6     $ 5  
Research and development                 2  
Selling, general and administrative     825       519       422  
    $ 831     $ 525     $ 429